-
公开(公告)号：US11925629B2
公开(公告)日：2024-03-12
申请号：US17368559
申请日：2021-07-06
Applicant: Asana Biosciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy , Raghava Reddy Kethiri , Purushottam M. Dewang , Gurulingappa Hallur , Chandrika Mulakala
IPC: A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , C07D401/04
CPC classification number: A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , C07D401/04
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
公开(公告)号：US11434278B2
公开(公告)日：2022-09-06
申请号：US16382735
申请日：2019-04-12
Applicant: Asana BioSciences, LLC
Inventor： Roger A. Smith , Nitin K. Damle , Aleksandr V. Yurkovetskiy , Mao Yin , Timothy B. Lowinger , Joshua D. Thomas , Cheri A. Stevenson , Venu R. Gurijala
Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
-
公开(公告)号：US20200179356A1
公开(公告)日：2020-06-11
申请号：US16790082
申请日：2020-02-13
Applicant: Asana BioSciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy , Raghava Reddy Kethiri , Purushottam M. Dewang , Gurulingappa Hallur , Chandrika Mulakala
IPC: A61K31/443 , A61K31/444 , A61K31/4439 , A61K31/5377 , C07D401/04 , A61K31/506
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
公开(公告)号：US10316080B2
公开(公告)日：2019-06-11
申请号：US14512275
申请日：2014-10-10
Applicant: Asana Biosciences, LLC
Inventor： Roger A. Smith , Nitin K. Damle , Aleksandr V. Yurkovetskiy , Mao Yin , Timothy B. Lowinger , Joshua D. Thomas , Cheri A. Stevenson , Venu R. Gurijala
Abstract: A polymeric scaffold useful for conjugating with a protein based recognition-molecule (PBRM) to form a PBRM-polymer-drug conjugate is described herein. The scaffold includes one or more terminal maleimido groups. Also disclosed is a PBRM-polymer-drug conjugate prepared from the scaffold. Compositions comprising the conjugates, methods of their preparation, and methods of treating various disorders with the conjugates or their compositions are also described.
-
公开(公告)号：US09533981B2
公开(公告)日：2017-01-03
申请号：US14078612
申请日：2013-11-13
Applicant: Asana Biosciences, LLC
Inventor： Roger A. Smith , Nicholas James Laping , Aranapakam M. Venkatesan , Raghava Reddy Kethiri , Chandregowda Venkateshappa , Bheemashankar Kulkarni , Purushottam Dewang , Rajendra Kristam , Rajesh Devraj
IPC: A61K31/4965 , C07D401/14 , C07D213/30 , C07D417/06 , C07D213/84 , C07D401/06 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/14
CPC classification number: C07D417/06 , C07D213/30 , C07D213/84 , C07D401/06 , C07D401/14 , C07D405/14 , C07D409/14 , C07D413/06 , C07D417/04 , C07D417/14
Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.
Abstract translation: 本申请提供了新颖的吡啶化合物及其药学上可接受的盐或前药。 还提供了制备这些化合物的方法。 通过向患者施用治疗有效量的一种或多种化合物，这些化合物可用于抑制CYP17活性。 通过这样做，这些化合物在治疗与CYP17活性相关的病症中是有效的。 可以使用这些化合物治疗多种病症，并且包括以异常细胞增殖为特征的疾病。 在一个实施方案中，该疾病是癌症，例如前列腺癌。
-
Patent Agency Ranking
公开(公告)号：US20160362406A1
公开(公告)日：2016-12-15
申请号：US15183486
申请日：2016-06-15
Applicant: Asana Biosciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy
IPC: C07D417/14 , A61K31/506 , C07D405/14 , C07D401/04 , C07D413/14 , A61K31/444 , C07D409/14 , C07D403/14 , C07C309/30 , A61K31/4439 , C07D401/14 , C07D403/04 , A61K31/5377
CPC classification number: C07D417/14 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , C07C309/30 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
公开(公告)号：US10751332B2
公开(公告)日：2020-08-25
申请号：US15183504
申请日：2016-06-15
Applicant: Asana Biosciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy , Raghava Reddy Kethiri , Purushottam M. Dewang , Gurulingappa Hallur , Chandrika Mulakala
IPC: A61K31/443 , A61K31/506 , C07D401/04 , A61K31/5377 , A61K31/4439 , A61K31/444
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
公开(公告)号：US10471051B2
公开(公告)日：2019-11-12
申请号：US15694124
申请日：2017-09-01
Applicant: Asana Biosciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy , Raghava Reddy Kethiri , Purushottam M. Dewang , Gurulingappa Hallur , Chandrika Mulakala , Ramesh Mullangi , Mohd Zainuddin
IPC: A61K31/506 , A61K31/443 , C07D401/04 , A61K31/5377 , A61K31/4439 , A61K31/444
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
公开(公告)号：US09896445B2
公开(公告)日：2018-02-20
申请号：US15183486
申请日：2016-06-15
Applicant: Asana Biosciences, LLC
Inventor： Aranapakam M. Venkatesan , Scott K. Thompson , Roger A. Smith , Sanjeeva P. Reddy , Raghava Reddy Kethiri , Purushottam M. Dewang , Gurulingappa Hallur , Chandrika Mulakala , Ramesh Mullangi , Mohd Zainuddin
IPC: A61K31/443 , C07D401/04 , C07D417/14 , C07D403/04 , A61K31/506 , C07D405/14 , C07D413/14 , A61K31/5377 , C07D409/14 , C07D403/14 , C07C309/30 , A61K31/4439 , C07D401/14 , A61K31/444
CPC classification number: C07D417/14 , A61K31/443 , A61K31/4439 , A61K31/444 , A61K31/506 , A61K31/5377 , C07C309/30 , C07D401/04 , C07D401/14 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14
Abstract: The present application provides novel heterocyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful for inhibiting ERK1/2. By administering to a patient in need a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, Z, J, M, and R1 to R8 are defined herein, these compounds are effective in treating conditions associated with dysregulation of the RAS/RAF/MEK/ERK pathway. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
10.发明申请公开(公告)号：US20170290838A1
公开(公告)日：2017-10-12
申请号：US15581330
申请日：2017-04-28
Applicant: Asana BioSciences, LLC
Inventor： Scott K. Thompson , Roger A. Smith , Sanjeeva Reddy , Tyler M. John , Vijay Kumar Nyavanandi , Hosahalli Subramanya , Vijay Potluri , Sunil Kumar Panigrahi , Prabhakara Rao Nadipalli , Saumitra Sengupta
IPC: A61K31/5377
CPC classification number: A61K31/5377 , A61K45/06 , C07D239/94 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D409/14 , C07D413/14 , C07D471/04 , C07D519/00 , G01N33/5011 , G01N33/57496
Abstract: The present application provides novel quinazolines and azaquinazolines and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in for co-regulating RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways by administering a therapeutically effective amount of one or more of the compounds of formula (I), wherein X, Y, T and R4, and R6 to R8′ are defined herein, to a patient. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathways. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer.
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.061 seconds)
